key: cord-0877798-igcuspgs
authors: Mhawish, Huda; Mady, Ahmed; Alaklobi, Faisal; Aletreby, Waleed; Asad, Tasmiya; Alodat, Mohammed; Alharthy, Abdulrahman; Abdulrahman, Basheer; Almahwi, Saleh; Memish, Ziad A.
title: Comparison of severity of immunized versus non-immunized COVID-19 patients admitted to ICU: A prospective observational study
date: 2021-10-15
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2021.102951
sha: 166346d3fe3abd79193e20e372ba17e510000a8d
doc_id: 877798
cord_uid: igcuspgs

BACKGROUND: Vaccines against COVID-19 show high efficacy, yet, infection is still being detected among immunized patients, although with blunted severity. The purpose of this study was to assess the severity of COVID-19 infection among immunized versus non-immunized COVID-19 patients admitted to ICU. METHOD: A prospective observational cohort study, including all COVID-19 patients admitted to intensive care unit between January 1st, 2021 and June 30th, 2021 were eligible for inclusion. A comparison of severity upon hospitalization of immunized versus non-immunized patients on a 7-level ordinal scale was conducted, using ordinal logistic regression. RESULTS: 592 patients were enrolled, 524 (88.5%) non-immunized, 63 (10.6%) partially immunized, and 5 (0.9%) fully immunized, partially and fully immunized patients were grouped together. Majority of immunized patients (86.7%) were symptomatic before 21 days of immunization. Non-immunized group had fewer patients in the lower severity categories, while more patients in the higher severity categories compared to immunized group. At least one dose of immunization was associated with reduction of odds of moving up severity scale (OR = 0.2 [95% CI: 0.15–0.4]; p < 0.001) in a well fitted ordinal logistic regression model. At least one dose of immunization was associated with lower adjusted odds of 30 day all-cause mortality (OR = 0.45 [95% CI: 0.23–0.89]; p = 0.02). Non-immunized group had higher mortality rate (43.9% versus 29.4% [95% CI: 1.5 to 25.8]; p = 0.02). CONCLUSION: Most COVID-19 patients admitted to ICU were non-immunized, most of the partially immunized patients got infected before immunity could develop, and fully immunized patients were likely non-responders. At least one dose of immunization significantly decreases severity of the disease across all ordinal severity categories, and is significantly associated with lower 30 day all-cause mortality. Accordingly, immunization status may have to be considered when deciding on disposition of COVID-19 patients at the point of triage.

prospective cohort study concluded that COVID-19 vaccinated cases will suffer lower duration of illness, and risk of febrile symptoms (9).

Most of the studies on post-vaccination hospitalized COVID-19 cases evaluate their severity by ICU admission, mechanical ventilation, and mortality (7, 12, 13). To our best knowledge, no study has attempted to objectively determine the severity of COVID-19 infection among vaccinated patients admitted to ICU, hence; this study was carried out under the hypothesis that among COVID-19 patients admitted to ICU, vaccinated patients may have a lower disease severity compared to unvaccinated.

This was a prospective observational cohort study, performed at the ICU of King Saud Medical City (KSMC). KSMC is the largest government hospital in the central region of Saudi Arabia, harboring 1200 beds. The ICU originally included 127 beds, and was expanded to accommodate the surge in COVID-19 patients during the second wave (as of January 2021), to include 300 beds. It is a closed ICU, operated by intensivists round the clock, with a 1:1 Nurse to patient ratio. Since the beginning of the COVID19 era, KSMC has been a COVID-19 referral center, generally following COVID-19 management recommendations issued by the Ministry of Health Data management: For all enrolled patients during the study period we collected baseline demographic and chronic health conditions (age, gender, nationality, and comorbidities).

Furthermore, we noted the clinical characteristics upon admission to the hospital, this included vital signs, peripheral oxygen saturation on room air (SpO2), supplemental oxygen requirement (provided at the discretion of the treating physician to maintain SpO2 ≥ 94%), and respiratory rate. This enabled categorization of patients based on severity upon hospital admission according to an ordinal scale (15) . Enrolled patients were followed for their period of hospital stay.

Initially, we planned to group patients according to immunization status into 3 groups (No immunization, single dose, and two doses), however; by the conclusion of the study period, we have enrolled only five patients with two doses of immunization, accordingly; we divided the patients into two groups of either no immunization, or at least one dose to avoid disadvantages of a small sized group in the statistical analysis (16) . The manufacturer of the vaccine was not taken into consideration (COVID-19 vaccines approved in Saudi Arabia at the time of the study are Pfizer ® and Astra-Zineca ®), we also recorded the duration between the last dose of vaccination (for vaccinated patients) and first development of symptoms. Treatment variables were recorded in terms of general medications groups, to include: Tocilizumab, Steroids, and Antivirals.

Finally, each patient's 30 day outcome was recorded as a binary dead or alive variable, along with hospital and ICU length of stay (LOS). Patients transferred to other hospitals were not followed there, and were considered as alive discharge from our hospital.

Outcomes: The primary outcome of the study was to compare severity of admission among COVID-19 patients admitted to ICU according to immunization status. Secondary outcomes included, 30 day all-cause mortality, ICU and hospital LOS, and requirement of mechanical ventilation upon ICU admission.

Continuous variables were summarized as mean ± standard deviation (SD) and median interquartile range (IQR), and were compared between groups by student t test or Mann Whitney U test as appropriate without normalization, discrete variables were summarized as frequency and percentage (%), and were compared between groups by chi square test or Fisher's exact test as appropriate, without correction for multiple testing. Test results were presented with corresponding 95% confidence interval (CI) of difference, and p values.

The primary outcome of severity ordinal scale was evaluated using proportional odds model for ordinal outcomes, presenting results as odds ratio (OR) adjusted for age and gender, likelihood ratio test was used to evaluate the parallel regression assumption (assumption holds if p > 0.05).

Whereas the association of immunization status with 30 day mortality was explored in a logistic regression model, initially, all significant variables were identified in a univariable model, and the final multivariable model included variables with p < 0.1 in the univariable model, with evaluation of fulfilment of the assumptions of logistic regression and goodness of fit (details in supplementary file).

All statistical tests were two tailed, and considered significant with p values < 0.05. Statistical 

During the study period there were 611 admissions to ICU with confirmed COVID-19 diagnosis, seven pregnant ladies, and 12 minor patients were excluded, leaving 592 patients to be enrolled. 524 (88.5%) patients have not received any immunization, 63 (10.6%) patients received a single dose, and only five patients (0.9%) received two doses of immunization (Figure 1 ), the average duration between the last immunization dose and first appearance of symptoms was 13.5 ± 6.7 days (for 68 patients, figure S1), with majority of patients (86.8%) showing symptoms within 21 days of vaccination (figure S2), notably, all five patients with two doses of immunization showed symptoms after more than 21 days of the second dose. Due to our prospective follow up of enrolled patients, there were no missing data. The patients were grouped into two groups of No immunization (thereafter called group 1) and at least one dose of immunization (thereafter called group 2). Demographic and clinical characteristics of both groups were similar with the exception of a higher percentage of patients in group 2 with three or more comorbidities (Table   1) , the similarity of both groups with regards to demographic and management modalities may be an indication that medications received in ICU may not be confounding factors.

Primary outcome: Table 1 and Figure S3 show the distribution of the ordinal scale of severity upon admission across the two groups. Group 1 had significantly lower percentages than group 2 in the lower two categories (categories 3 and 4), while higher percentages were observed in the higher two categories (categories 5 and 6). Immunization status (adjusted for age and gender) Secondary outcomes: The percentage of patients requiring MV upon ICU admission was higher in group 1 than group 2, however, the difference didn't reach statistical significance (26.9% Vs 19.1%, 95% CI: -4.2% to 17.2%; p = 0.2). In group 1 all-cause 30 day mortality was 230/524 (43.9%), while that for group 2 was 20/68 (29.4%), the difference was statistically significant (95% CI: 1.5 to 25.8; p = 0.02). On the contrary, neither ICU nor hospital LOS was different between both groups (Table 1) Several variables were identified to be associated with 30 day mortality in univariable logistic regression, including: Age, immunization status, number of comorbidities, severity of admission, MV on admission, diabetes mellitus, hypertension, chronic kidney disease, coronary heart disease, and heart failure or arrhythmia. When all the variables were evaluated in a multivariable logistic regression model, immunization status was significantly associated with reduction of the odds of 30 day mortality (OR 0.45 [95% CI: 0.23 to 0.89]; p = 0.02) ( Table 3) Figure S4 ).

In this study we examined the data of 592 COVID-19 positive patients admitted to the ICU during the study period, there was an obvious predominance of unvaccinated patients in the cohort, with only about 11% who had received at least one dose of vaccination. This is not surprising as both vaccine brands authorized in Saudi Arabia have already demonstrated excellent efficacy in RCTs (4, 5). Despite the fact that the majority of the vaccinated group were partially immunized, being a minority in the whole cohort is comprehendible, as several studies demonstrated vaccine efficacy between 80% and 91% after the first dose (18, 19) . The J o u r n a l P r e -p r o o f immunized group slightly differed from the non-immunized by including significantly more patients with three or more comorbidities, which places them at a higher risk of COVID-19 infection compared to others (11, 20) . More importantly, most of the patients who had received at least one dose of vaccination presented with symptoms and were hospitalized within less than 21 days of their vaccination as immunity develops over time. During the first two to three weeks after the first dose of vaccination efficacy is much lower than afterwards (7), as spike immunoglobulins G (IgG) begin to appear around this period (13). Infection of partially immunized patients within 2-3 weeks of immunization -rather than afterwards -is a common finding in many studies on post vaccination COVID-19 cases (13, 21). In our cohort there were five patients who were fully immunized, they presented after 21 days had passed since their last immunization dose, leading to the assumption that those patients were non-responders (sometime referred to as breakthrough infections), since most COVID-19 vaccines are based on the development of spike IgG antibodies, their efficacy may be attenuated by antigen mutation (12), and it was during the study period that new variantspossibly with antigen mutationstarted to appear worldwide, and possibly in Saudi Arabia (22).

The majority of clinical trials on post-vaccination COVID-19 addressed severity of the disease in terms of either symptomatic or asymptomatic presentation, or count of events of hospitalization, ICU admission, mechanical ventilation, or death (7, 9, 11, 13, 23, 24), unanimously concluding lower severity (according to the design of each study) in the group of immunized patients. This was also true for our secondary outcome of all-cause 30 day mortality, which was significantly lower in the immunized group. However, for our primary outcome, we chose to be more through regarding categorization of severity upon hospital admission utilizing an ordinal scale of severity that was previously applied to COVID-19 patients (15) , and by applying ordinal regression, we J o u r n a l P r e -p r o o f demonstrated that immunization by at least one dose of vaccination is not only associated with lower severity upon hospitalization, but it uniformly lowers the odds of moving from one category to the next, that is to say, the effect of the independent variable (at least one dose of immunization in this case) has the same effect on any pair of consecutive outcomes of the ordinal scale (25) . Accordingly, our modelwhich we believe is unprecedented -indicates that at least one dose of immunization decreases the odds of changing from severity category 3 to 4, 4 to 5, and 5 to 6 by 80%. The mechanism, however; by which partial immunization attenuates the disease remains mostly unknown, with hypotheses based on other types of vaccines suggesting reduction of viral replication, and rapid elimination of infected cells through recall of immunologic memory responses (10, 26). In support of this finding, was the results of well fitted multivariable logistic regression model showing that at least one dose of immunization lowers the adjusted odds of 30 day all-cause mortality by 55%.

Our study suffers numerous limitations, this was an observational study lacking the advantages of randomization due to obvious ethical reasons, however; statistical methods could be used in future studies such as propensity score matching or emulation studies to produce more valid results. The sample size is relatively small and may have affected the power of the study, although this was possibly compensated for by rigorous statistical model. This was a single center study, reflecting the management of only one hospital. Also data on variants and impact on disease severity is lacking. And finally, our analysis lacks subdivision of immunized patients by duration since vaccination, which could have produced more informative results.

In our study the majority of COVID-19 patients admitted to ICU were non-immunized, most of the partially immunized patients got infected before immunity could develop, and the minute J o u r n a l P r e -p r o o f percentage of fully immunized patients probably were non-responders. Receiving at least one dose of immunization significantly decreases severity of the disease across all ordinal severity categories. Furthermore, at least one dose of immunization is significantly associated with lower 30 day all-cause mortality. Policy makers and clinicians may need to take the immunization status in consideration when deciding on disposition of COVID-19 patients to ICU or general ward.

All authors declare no conflict of interests.

The study was approved by the local institutional review board (Reference number: H1R1-22-June 21-04) with waiver of consent in view of its observational design

No external funding was received for this work.

The study team would like to extend their gratitude to the following for their efforts in data collection and general support of the project: J o u r n a l P r e -p r o o f 

COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

How sample size influences research outcomes

Guideline: Strengthening the Reporting of Cohort Studies in Surgery

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. Elife

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

Using the proportional odds model for health-related outcomes: Why, When, and How with various SAS procedures, Paper presented at SAS Users Group International, thirty annual conference

Highlights • Vaccines against COVID-19 show high efficacy in preventing hospitalization and death. • In our report most COVID-19 patients admitted to ICU were non-immunized

At least one dose of immunization significantly decreases severity of the disease. • Most of the partially immunized patients got infected before immunity could develop, and fully immunized patients were likely non-responders

J o u r n a l P r e -p r o o f

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement. Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.All authors contributed equally J o u r n a l P r e -p r o o f

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

Name of the registry: Research Registry 2. Unique Identifying number or registration ID: 71623. Hyperlink to your specific registration (must be publicly accessible and will be checked):https://www.researchregistry.com/browse-the-registry#home/

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish